中西医结合治疗晚期非小细胞肺癌的成本效果分析

杨宏丽

doi:10.13288/j.11-2166/r.2007.03.018

您当前的位置：

首页 >

文章列表页 >

中西医结合治疗晚期非小细胞肺癌的成本效果分析

百家园 | 更新时间：2021-11-17

- 中西医结合治疗晚期非小细胞肺癌的成本效果分析
- Cost-Effect Analysis of Integrated Chinese and Western Medical Treatment for Advanced Non-small Cell Lung Cancer
- 中医杂志 2007年第3期页码：232-234
- 作者机构：
  
  1. 中国医学科学院/中国协和医科大学肿瘤医院中医科北京市朝阳区潘家园南里17号
  2. ,100021
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2007.03.018
  中图分类号： R734.2
- 纸质出版：2007
- 稿件说明：
移动端阅览
[1]杨宏丽.中西医结合治疗晚期非小细胞肺癌的成本效果分析[J].中医杂志,2007(03):232-234.

YANG Hong-li. Cost-Effect Analysis of Integrated Chinese and Western Medical Treatment for Advanced Non-small Cell Lung Cancer[J]. Journal of Traditional Chinese Medicine2007, (3): 232-234.
[1]杨宏丽.中西医结合治疗晚期非小细胞肺癌的成本效果分析[J].中医杂志,2007(03):232-234. DOI： 10.13288/j.11-2166/r.2007.03.018.

YANG Hong-li. Cost-Effect Analysis of Integrated Chinese and Western Medical Treatment for Advanced Non-small Cell Lung Cancer[J]. Journal of Traditional Chinese Medicine2007, (3): 232-234. DOI： 10.13288/j.11-2166/r.2007.03.018.

摘要

目的探讨中西医结合与单纯西医治疗晚期非小细胞肺癌（NSCLC）的成本效果比。方法符合入选标准的77例NSCLC患者随机分为中西医组38例、西医组39例。中西医组用生脉注射液、梅花点舌丸联合NP（异长春花碱+顺铂）方案化疗;西医组为单纯NP方案化疗。比较两组的治疗成本、一年生存率及成本效果比。结果中西医组的成本/肿瘤控制率和成本/一年生存率（C/E）分别为552.19和1104.51;西医组该两项分别为595.68和1299.56。结论中西医结合治疗晚期NSCLC有较好的成本效果比。

Abstract

Objective To observe cost-effect ratios of integrated Chinese and western medical treatment and simple western medical treatment for advanced non-small cell lung cancer（NSCLC）.Methods Totally 77 cases of advanced NSCLC were randomly divided into Chinese and western medicine group and western medicine group.Western medicine group of 39 cases was treated with chemotherapy of Vinorelbine and DDP

while Shengmai Injection and Meihua Dianshe Pill were added to 38 cases in Chinese and western medicine group.Therapeutic cost

one-year survival rate and cost-effect ratio were compared between two groups.Results Cost-tumor control rate ratio and cost-one year survival rate ratio were 552.19 and 1104.51 in Chinese and western medicine group

while 595.68 and 1299.56 in western medicine group respectively.Conclusion Integrated Chinese and western medical treatment for advanced NSCLC has better cost-effect ratio.

关键词

Keywords

references

查看原文

浏览量

248

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中医辨证治疗对晚期非小细胞肺癌巩固治疗的影响

六君子汤加减辅助化疗治疗晚期非小细胞肺癌31例临床观察

江苏中医优势病种诊疗方案治疗成人非重症社区获得性肺炎患者1293例临床疗效及经济学评价——一项多中心、回顾性真实世界队列研究

“欲食”“能食”“喜食”之“问食”三要的内涵与应用

中医药去中心化临床试验关键技术实施的挑战与建议